Core Insights - In 2024, China's innovative drug license-out transaction amount exceeded $51.9 billion, with emerging technology pipelines like ADC, bispecific antibodies, and CGT accounting for over 30% of global research projects, indicating China's transition from a "technology follower" to an "innovation source" [2] - The ongoing unmet clinical needs globally are driving multinational corporations (MNCs) to accelerate collaborations with Chinese pharmaceutical companies [2] - Despite the optimistic outlook, companies must focus on adapting to changing international policies and optimizing resource allocation to balance innovation and commercialization efficiency during their internationalization journey [2] Event Overview - The 2025 CPHI China Biotech Exhibition will feature high-quality thematic conferences, including the "10th CPHI Biopharmaceutical Forum" and "New Forces, New Journey - CPHI Innovative Drug Going Global Forum," gathering industry leaders from companies like BeiGene, Zai Lab, and Biocon [2][5] - The event aims to analyze the global biopharmaceutical industry landscape, from regulation to research, and promote collaboration across the entire chain from laboratory research to large-scale production [5] Conference Agenda Highlights - The conference will take place from June 24-25, 2025, at the Shanghai New International Expo Center, featuring sessions on topics such as the development trends of Chinese biopharmaceuticals, the future of biomanufacturing, and strategies for international cooperation [6][11] - Keynote speakers include experts from various sectors, discussing clinical trial strategies, market trends, and the impact of capital on innovation in the biopharmaceutical field [7][12] Focus Areas - The event will emphasize "frontier therapies," particularly in the fields of peptide drugs and cell and gene therapy (CGT), aiming to connect research, production, clinical applications, and internationalization [21] - The conference will also explore the opportunities and challenges of Chinese innovative drugs entering international markets, particularly in Southeast Asia, Latin America, and the Middle East [12][13]